VRTX

+ Watchlist + Portfolio

Vertex Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $552.06
52-Week Range: $374.17 – $553.69
Market Cap: $136.93B
P/E (TTM): 31.47
EPS (TTM): 17.17
Dividend Yield: —

Advanced Metrics

Price/Book: 6.76
PEG Ratio: 1.91
Return on Equity: 23.54%
Return on Assets: 11.93%
Gross Margin: 54.96%
Operating Margin: 38.05%
Profit Margin: 35.00%
Current Ratio: 3.19
Debt/Equity: 0.10
Total Debt: $1.98B
Free Cash Flow: $2.63B
Revenue Growth: 12.50%
Earnings Growth: 8.00%
Enterprise Value: $134.05B

VRTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.93B	$9.87B	$11.02B	$12.00B
Cost of Revenue	$1.08B	$1.26B	$1.53B	$1.65B
Gross Profit	$7.85B	$8.61B	$9.49B	$10.35B
Research & Development	$2.66B	$3.69B	$8.26B	$4.04B
Selling, General & Admin	$944.70M	$1.14B	$1.46B	$1.75B
Operating Expenses	$3.60B	$4.83B	$9.72B	$5.80B
Operating Income	$4.25B	$3.78B	-$233.40M	$4.55B
EBITDA	$4.44B	$4.61B	$486.30M	$4.87B
Pretax Income	$4.23B	$4.38B	$248.50M	$4.64B
Income Tax	$910.40M	$760.20M	$784.10M	$690.00M
Net Income	$3.32B	$3.62B	-$535.60M	$3.95B
Diluted EPS	12.82	13.89	-2.08	15.32
Diluted Shares	259.10M	260.50M	257.90M	258.00M

VRTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.50B	$10.37B	$4.57B	$5.08B
Receivables	$1.44B	$1.56B	$1.61B	$2.05B
Inventory	$460.60M	$738.80M	$1.21B	$1.69B
Current Assets	$13.23B	$14.14B	$9.60B	$11.20B
Total Assets	$18.15B	$22.73B	$22.53B	$25.64B
Current Liabilities	$2.74B	$3.55B	$3.56B	$3.86B
Total Debt	$899.70M	$808.40M	$1.74B	$2.03B
Total Liabilities	$4.24B	$5.15B	$6.12B	$6.98B
Retained Earnings	$6.52B	$10.14B	$9.61B	$13.56B
Shareholders' Equity	$13.91B	$17.58B	$16.41B	$18.67B
Working Capital	$10.49B	$10.60B	$6.03B	$7.34B

VRTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$4.13B	$3.54B	-$492.60M	$3.63B
Capital Expenditure	-$204.70M	-$258.40M	-$485.40M	-$437.60M
Free Cash Flow	$3.93B	$3.28B	-$978.00M	$3.19B
Depreciation & Amortisation	$148.30M	$181.30M	$207.20M	$209.80M
Stock-Based Compensation	$491.30M	$581.20M	$698.50M	$685.90M
Investing Cash Flow	-$321.10M	-$3.14B	-$3.77B	-$945.40M
Financing Cash Flow	-$67.70M	-$562.20M	-$1.49B	-$2.26B
Share Repurchases	-$172.00M	-$653.70M	-$1.58B	-$2.39B
Net Change in Cash	$3.74B	-$166.60M	-$5.76B	$424.70M

VRTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.77B	$2.96B	$3.08B	$3.19B	$2.99B
Cost of Revenue	$363.00M	$407.50M	$414.80M	$466.00M	$392.80M
Gross Profit	$2.41B	$2.56B	$2.66B	$2.72B	$2.59B
Research & Development	$979.70M	$978.40M	$977.70M	$1.11B	$961.60M
Selling, General & Admin	$396.40M	$424.60M	$445.10M	$487.00M	$493.70M
Operating Expenses	$1.38B	$1.40B	$1.42B	$1.59B	$1.46B
Operating Income	$1.03B	$1.15B	$1.24B	$1.13B	$1.14B
EBITDA	$1.08B	$1.34B	$1.36B	$1.39B	$1.19B
Pretax Income	$730.40M	$1.28B	$1.30B	$1.33B	$1.25B
Income Tax	$84.10M	$250.10M	$215.90M	$139.90M	$221.50M
Net Income	$646.30M	$1.03B	$1.08B	$1.19B	$1.03B
Diluted EPS	2.49	3.99	4.20	4.65	4.02
Diluted Shares	259.50M	258.90M	257.60M	256.10M	256.30M

VRTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.67B	$4.97B	$4.94B	$5.08B	$5.49B
Receivables	$1.81B	$1.89B	$1.95B	$2.05B	$2.00B
Inventory	$1.36B	$1.50B	$1.63B	$1.69B	$1.77B
Current Assets	$10.01B	$10.43B	$10.57B	$11.20B	$11.73B
Total Assets	$22.88B	$24.04B	$24.86B	$25.64B	$26.48B
Current Liabilities	$3.78B	$4.14B	$4.48B	$3.86B	$3.88B
Total Debt	$1.65B	$1.53B	$1.83B	$2.03B	$1.99B
Total Liabilities	$6.38B	$6.86B	$7.54B	$6.98B	$7.12B
Retained Earnings	$10.25B	$11.29B	$12.37B	$13.56B	$14.59B
Shareholders' Equity	$16.50B	$17.18B	$17.32B	$18.67B	$19.36B
Working Capital	$6.23B	$6.29B	$6.09B	$7.34B	$7.85B

VRTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$818.90M	$1.07B	$1.24B	$498.00M	$1.43B
Capital Expenditure	-$40.70M	-$145.70M	-$101.80M	-$149.40M	-$133.40M
Free Cash Flow	$778.20M	$927.40M	$1.14B	$348.60M	$1.29B
Depreciation & Amortisation	$48.40M	$51.70M	$54.00M	$55.70M	$55.90M
Stock-Based Compensation	$166.10M	$167.30M	$194.90M	$157.60M	$166.40M
Investing Cash Flow	-$55.80M	-$484.50M	-$117.00M	-$288.10M	-$431.90M
Financing Cash Flow	-$680.40M	-$349.20M	-$1.15B	-$77.20M	-$538.80M
Share Repurchases	-$696.60M	-$397.70M	-$1.16B	-$130.90M	-$565.40M
Net Change in Cash	$82.70M	$239.40M	-$30.10M	$132.70M	$457.40M

Market Snapshot

About

Vertex Pharmaceuticals Inc. is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines for cystic fibrosis and is advancing clinical and research programs in pain, sickle cell disease, beta thalassemia, and other serious conditions. Vertex is known for its pioneering work in developing precision medicines that address the underlying causes of genetic diseases.